Skip to main content
OpenTrials
Completed

NCT Number: NCT00755014

Study Effect of Red Wine Consumption on Endothelial Progenitor Cells and Endothelial Function

Light-to-moderate alcohol consumption has been associated with a reduction of cardiovascular events, and red wine seems to offer more benefits than any other type of alcoholic beverages. However, the relationship between red wine consumption and endothelial progenitor cells (EPCs) remains unclear. The investigators examine whether intake of red wine could enhance the number or functional capacity of circulating EPCs by upregulation of nitric oxide (NO) bioavailability.

Completed

Looking for future studies?

Notify Me

Key information

Age range

20 year–40 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Taipei Veterans Generla Hospital

Taipei, 112, Taiwan

About this study

Moderate ethanol intake from any type of beverage has been shown to improve lipoprotein metabolism and lower cardiovascular mortality risk, but red wine, with its abundant antioxidant contents, seems to confer additional healthy benefits. Previous studies indicated that the beneficial effects of red wine are derived from increased endothelium-derived nitric oxide (NO), implying that enhanced NO bioavailability may mediate the cardiovascular protection provided by red wine.

Increasing evidence suggests that the injured endothelial monolayer is regenerated partly by circulating bone marrow derived-endothelial progenitor cells (EPCs), which accelerate reendothelialization and protect against the initiation and progression of atherosclerosis. Clinical studies demonstrated that the number of circulating EPCs predicts the occurrence of cardiovascular events and death from cardiovascular causes and may help to identify patients at increased cardiovascular risk. Although many epidemiologic studies have indicated that light-to-moderate consumption of red wine can reduce the incidence of CAD, the multifarious effects of red wine on circulating EPCs and endothelial function remain to be determined. Therefore, we design this study to test the hypothesis that intake of red wine can enhance the number and functional capacity of EPCs through increasing NO bioavailability.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Forty young healthy subjects with no cardiovascular risk factors

Exclusion criteria

  • History of hypertension
  • Diabetes mellitus
  • Symptoms of CAD
  • Smoking
  • Chronic renal insufficiency (serum creatinine > 1.5 mg/dl)
  • Inflammatory or liver diseases
  • Regular alcohol consumption (drinking more than 20 g of ethanol per week)

Treatment and study plan

Red Wine

Other

One group (n=20) that consumed red wine (100 ml) daily for 3 weeks Another group (n=20) that consumed beer (250 ml) daily for 3 weeks

Other names: The red wine used is "Vin De Pays D'OC" (12.5% ethanol), a cabernet sauvignon from France, The beer used was Taiwan Beer (5% alcohol) from Taiwan.

Primary outcomes

  1. Number of endothelial progenitor cells, endothelial function (FMD)

    Time frame: VGH-97DHA0100127

Secondary outcomes

  1. Plasma NO, hsCRP, ADMA, TNF-a, adiponectin, ox-LDL levels

    Time frame: VGH-97DHA0100127

Sponsors and collaborators

Lead sponsor

Taipei Veterans General Hospital, Taiwan

Other Gov

Collaborators

  • National Yang Ming Chiao Tung University

Registry information

Official study title

Taipei Veterans General Hospital

Important dates

Study start
2007
Primary completion
2008
Study completion
2008
First posted
Sep 18, 2008
Registry last updated
Sep 18, 2008

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.